HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $13.24 and traded as low as $13.14. HUTCHMED shares last traded at $13.15, with a volume of 33,492 shares trading hands.

Analysts Set New Price Targets

Several research analysts recently issued reports on HCM shares. The Goldman Sachs Group dropped their price objective on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. Weiss Ratings upgraded HUTCHMED from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, October 20th. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Daiwa Securities Group upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research note on Thursday, September 3rd. Finally, Bank of America decreased their price objective on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.87.

HUTCHMED Stock Performance

The stock’s 50 day moving average price is $13.65 and its 200-day moving average price is $13.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The company had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million. On average, equities analysts predict that HUTCHMED will post 0.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Janney Montgomery Scott LLC bought a new position in shares of HUTCHMED in the 1st quarter worth $365,000. XY Capital Ltd lifted its stake in shares of HUTCHMED by 115.2% during the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock worth $1,120,000 after purchasing an additional 55,736 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in HUTCHMED by 25.0% during the third quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company’s stock valued at $1,553,000 after purchasing an additional 21,270 shares in the last quarter. Finally, Amundi boosted its position in HUTCHMED by 4.0% during the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares in the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines research and development capabilities in China with international development and commercial operations, serving patients and healthcare providers in China, the United States, Europe and other global markets.

HUTCHMED’s oncology portfolio includes fruquintinib, a targeted therapy for certain patients with metastatic colorectal cancer.